Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

WST vs LYRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

WST Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

WST Overall Winner 6-Pillar Tally: WST 6 – 0 LYRA Matrix Metrics: WST 9 – 1 LYRA

As of Nov 17, 2026, West Pharmaceutical Services, Inc. (WST) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). WST carries a Unified Composite Score of 39.8/100 (SELL) at $413.28 (40.2x Forward P/E, 22.9% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin).

  • Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. WST 39.8/100 SELL), WST captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (22.9% vs. -25032.0% operating margin) and revenue trajectory (+8.7% vs. -87.2% YoY).
  • Technical & Structure Timing Caution: WST trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.6); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About WST vs LYRA
WST NYSE Head-to-Head Winner
West Pharmaceutical Services, Inc.
Surgical & Medical Instruments & Apparatus
$413.28
-1.08% 1D
Market Cap $29.0B
TTM Revenue $3.40B
Forward P/E 40.2x
Beta / 30D Vol 0.46β · 24% Vol
Unified Composite Score
39.8 / 100 SELL
Tech 26.0 Fund 34.0 Flow 54.0 Mom 1.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.6% over 20 days), RSI 64
RSI-14: 63.6 · SMA20: $406.03 · SMA50: $383.28
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
TTM Revenue $600,000
Forward P/E N/M
Beta / 30D Vol 0.33β · 248% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.27 · SMA50: $1.82

6-Pillar Scorecard Institutional Category Breakdown (WST 6 – 0 LYRA)

Columns: Metric · WST · LYRA
1. Valuation Multiples WST
Forward P/E 40.2x N/M
Trailing P/E 46.7x N/M
PEG Ratio 3.03x N/M
EV / Revenue 8.5x 3.9x
2. Growth & Scale WST
Revenue Growth (YoY) +8.7% -87.2%
Earnings Growth (YoY) +57.3% +0.0%
TTM Revenue (USD) $3.40B $600,000
Market Cap $29.0B $2.3M
3. Profitability & Quality WST
Gross Margin 37.6% N/A
Operating Margin 22.9% -25032.0%
Net Profit Margin 18.8% 0.0%
Return on Equity (ROE) 21.2% -404.5%
4. Balance Sheet & Cash Flow WST
Cash Generation (TTM) $453M -$32M EBITDA
Cash Flow Margin 13.3% N/A
Net Cash / Leverage $159M Net Cash -404.5% ROE
Dividend Yield 0.21% None (0.00%)
5. Options & Positioning WST
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 26.0% (13th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat WST
OpEx & R&D Intensity 14.7% of Rev ($499M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: WST (9) vs LYRA (1)
Institutional Metric WST LYRA Criterion Row Edge
Market Capitalization
Scale
$29.0B $2.3M Larger Scale WST
Trailing P/E Ratio
Valuation
46.7x N/M Lower Multiple WST
Forward P/E Ratio
Valuation
40.2x N/M Lower Multiple WST
Revenue Growth (YoY)
Growth
+8.7% -87.2% Higher Growth WST
Operating Margin (TTM)
Profitability
22.9% -25032.0% Higher Margin WST
Net Profit Margin
Profitability
18.8% 0.0% Higher Margin WST
Return on Equity (ROE)
Capital Efficiency
21.2% -404.5% Higher ROE WST
52-Week Range Position
Momentum
88% ($224–$438) 1% ($0–$38) Stronger Trend WST
Beta / 30D Volatility
Risk Regime
0.46β · 24% Vol 0.33β · 248% Vol Lower Realized Risk WST
Unified Institutional Score
Composite Signal
39.8 / 100 (SELL) 52.2 / 100 (HOLD) Higher Composite LYRA
Trailing 12M Revenue (USD)
Operating Scale
$3.40B $600,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
37.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.03x PEG · 8.5x EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$453M ($159M Net Cash) -$32M EBITDA (-404.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon WST +61.15 pp
WST: -1.35% · LYRA: -62.5%
3M Horizon WST +75.79 pp
WST: -11.83% · LYRA: -87.62%
6M Horizon WST +79.09 pp
WST: -8.05% · LYRA: -87.14%
1Y Horizon WST +79.09 pp
WST: -8.05% · LYRA: -87.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period WST Revenue LYRA Revenue WST Op. Margin LYRA Op. Margin Margin Leader
FY2018 $1.72B N/A 14.0% N/A WST
FY2019 $1.84B N/A 16.1% N/A WST
FY2020 $2.15B N/A 19.0% N/A WST
FY2021 $2.83B $0M 26.6% -15303.5% WST
FY2022 $2.89B $0M 25.4% -4131.0% WST
FY2023 $2.95B $0M 22.9% -4308.1% WST
FY2024 $2.89B $0M 19.7% -6280.8% WST
FY2025 $3.07B $0M 19.0% -7794.5% WST

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
WST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 26.0%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact WST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LYRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
WST Moat Profile Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $29.0B market capitalization and 22.9% operating margin.
OpEx & R&D Reinvestment 14.7% of Rev ($499M)
90D Engineering Disclosures 0 Published
LYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ WST vs LYRA Key Questions & Quantitative Answers

As of Nov 17, 2026, West Pharmaceutical Services, Inc. (WST) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). WST carries a Unified Composite Score of 39.8/100 (SELL) at $413.28 (40.2x Forward P/E, 22.9% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. WST 39.8/100 SELL), WST captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (22.9% vs. -25032.0% operating margin) and revenue trajectory (+8.7% vs. -87.2% YoY). Technical & Structure Timing Caution: WST trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.6); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

WST leads the Growth & Scale pillar: WST posts +8.7% YoY revenue growth and +57.3% YoY earnings growth on $3.40B TTM revenue (37.6% gross margin, 22.9% operating margin), compared with LYRA at -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), WST cumulative revenue shifted +78.5% while LYRA shifted N/A. In operating R&D and SG&A reinvestment, WST deploys 14.7% of Rev ($499M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LYRA.

WST screens cheaper on headline valuation multiples. WST trades at 40.2x Forward P/E, 46.7x Trailing P/E, 3.03x PEG, and 8.5x EV/Revenue (13.3% FCF margin), whereas LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WST (21.2% ROE) versus LYRA (-404.5% ROE) capital efficiency.

In options market volatility and institutional positioning, WST carries 26.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 24% Vol realized risk). By comparison, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.